Greg Ball
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Statistical Methods in Clinical Trials 16
-
- Health Systems, Economic Evaluations, Quality of Life 10
- Co-authors
- Hagop M. Kantarjian (5 shared papers)Francesco Onida (5 shared papers)Michael J. Keating (4 shared papers)Miloslav Beran (2 shared papers)Terry L. Smith (2 shared papers)Armand B. Glassman (2 shared papers)Maher Albitar (2 shared papers)Elihu H. Estey (2 shared papers)
- Journals
- Therapeutic Innovation & Regulatory Science (9 papers)Contemporary Clinical Trials (6 papers)Blood (3 papers)Journal of Neuroscience (2 papers)Pharmaceutical Statistics (2 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Greg Ball
32 papers receiving 841 citations
Peers
Comparison fields: 5 of 78
- Hematology 413
- Genetics 306
- Statistics and Probability 81
- Toxicology 31
- Rheumatology 88
Countries citing papers authored by Greg Ball
This map shows the geographic impact of Greg Ball's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Ball with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Ball more than expected).
Fields of papers citing papers by Greg Ball
This network shows the impact of papers produced by Greg Ball. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Ball. The network helps show where Greg Ball may publish in the future.
Co-authors
The 25 scholars most cited alongside Greg Ball, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 259 | |
| 2 | 2015 | 88 | |
| 3 | 2012 | 77 | |
| 4 | 2002 | 65 | |
| 5 | The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. | 2003 | 64 |
| 6 | 2008 | 45 | |
| 7 | 2016 | 28 | |
| 8 | 2013 | 27 | |
| 9 | 2003 | 27 | |
| 10 | 2017 | 24 | |
| 11 | 2016 | 24 | |
| 12 | 2016 | 17 | |
| 13 | 2011 | 13 | |
| 14 | 2011 | 11 | |
| 15 | 2002 | 10 | |
| 16 | 2021 | 9 | |
| 17 | 2011 | 9 | |
| 18 | 2004 | 8 | |
| 19 | 2019 | 8 | |
| 20 | 2020 | 6 |
About Greg Ball
Greg Ball is a scholar working on Statistics and Probability, Economics and Econometrics, Statistics, Probability and Uncertainty, Toxicology and Hematology, having authored 34 papers that have together received 861 indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (16 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmacovigilance and Adverse Drug Reactions (6 papers), Biosimilars and Bioanalytical Methods (5 papers), Meta-analysis and systematic reviews (5 papers), Acute Myeloid Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Hematology (413 citations), Genetics (306 citations), Statistics and Probability (81 citations), Toxicology (31 citations) and Rheumatology (88 citations). Greg Ball has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Hagop M. Kantarjian, Francesco Onida, Michael J. Keating, Miloslav Beran, Terry L. Smith, Armand B. Glassman, Maher Albitar, Elihu H. Estey, Monica Kwari and Barbara Scappini. Their work appears in journals such as Therapeutic Innovation & Regulatory Science, Contemporary Clinical Trials, Blood, Journal of Neuroscience and Pharmaceutical Statistics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.